APA

Thomas X., Raffoux E., Renneville A., Pautas C., de Botton S., Terre C., Gardin C., Hayette S., Preudhomme C. & Dombret H. (20100506). Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study. : Cancer.

Chicago

Thomas Xavier, Raffoux Emmanuel, Renneville Aline, Pautas Cecile, de Botton Stephane, Terre Christine, Gardin Claude, Hayette Sandrine, Preudhomme Claude and Dombret Herve. 20100506. Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study. : Cancer.

Harvard

Thomas X., Raffoux E., Renneville A., Pautas C., de Botton S., Terre C., Gardin C., Hayette S., Preudhomme C. and Dombret H. (20100506). Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study. : Cancer.

MLA

Thomas Xavier, Raffoux Emmanuel, Renneville Aline, Pautas Cecile, de Botton Stephane, Terre Christine, Gardin Claude, Hayette Sandrine, Preudhomme Claude and Dombret Herve. Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study. : Cancer. 20100506.